Company profile: Cartesian Therapeutics
1.1 - Company Overview
Company description
- Provider of potent, safer cell therapy in and beyond oncology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cartesian Therapeutics
Nuvation Bio
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical therapies addressing unmet needs, developing oral targeted candidates including Taletrectinib (CNS-active, selective next-generation ROS1 inhibitor for ROS1-positive NSCLC), Safusidenib (potent mIDH1 inhibitor for grades 2-3 IDH1-mutant glioma), NUV-868 (BD2-selective BET inhibitor targeting BRD4), and NUV-1511 (drug-drug conjugate candidate).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvation Bio company profile →
Tempest Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics that modulate anti-tumor pathways, including TPST-1120, an oral PPARα antagonist designed to inhibit fatty acid oxidation and inflammation with potential in hepatocellular, renal cell, and cholangiocarcinoma, and TPST-1495, an oral dual EP2/EP4 antagonist in Phase 1/1b combination studies to reduce tumor growth and immune suppression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tempest Therapeutics company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
Onco-NX
HQ: United Kingdom
Website
- Description: Provider of drug discovery research dedicated to identifying new promising anticancer agents as a University of Salford spin-out company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onco-NX company profile →
Theraclion
HQ: France
Website
- Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cartesian Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cartesian Therapeutics
2.2 - Growth funds investing in similar companies to Cartesian Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cartesian Therapeutics
4.2 - Public trading comparable groups for Cartesian Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →